Envisia Therapeutics to Present at ARVO 2015 Annual Meeting

Company Has Major Showing at World’s Largest Eye and Vision Conference

RESEARCH TRIANGLE PARK, N.C.--()--Envisia Therapeutics today announced that eight posters have been selected for presentation at the Association for Research in Vision and Ophthalmology’s (ARVO) Annual Meeting being held May 3 – 7, 2015 in Denver, Colorado. ARVO is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries. The theme of the ARVO 2015 Annual Meeting is Powerful Connections: Vision Research and Online Networking.

“We are proud to have been selected to present a comprehensive array of data, and are excited to participate in the quality scientific exchange at the ARVO Annual Meeting,” said Benjamin Yerxa, PhD, President of Envisia Therapeutics. “This broad body of work is representative of the unparalleled talent and technology that makes Envisia unique.”

Details related to Envisia presentations at ARVO are as follows:

Sunday, May 3, 2015

Poster #C0077: In-Vitro Release of Bevacizumab from Hydrogel-based Drug Delivery Systems

  • Exhibit Hall 192378 from 8:30am - 10:15am
  • Presented by Janet Tully, BS – Scientist, Analytical Sciences

Poster #C0085: Extended Release Bevacizumab Intravitreal Implant is Well Tolerated in the African Green Monkey

  • Exhibit Hall 192378 from 8:30am - 10:15am
  • Presented by Rose Verhoeven, MS – Director, Nonclinical Development

Poster #C0091: Establishing In Vivo to In Vitro Correlations for the Rate of Release of Bevacizumab from Extended Release Formulations

  • Exhibit Hall 192378 from 8:30am - 10:15am
  • Presented by Gary Owens, MS – Principal Scientist, Analytical Sciences

Wednesday, May 6, 2015

Poster #C0041: The Aseptic Fabrication of ENV515 (travoprost) Intracameral Implants

  • Exhibit Hall 192249 8:30am - 10:15am
  • Presented by Leo Trevino, PhD – Executive Director, Pharmaceutical Development

Poster #C0048: Sustained Release Biodegradable Steroid Formulations for Intravitreal Delivery

  • Exhibit Hall 192249 8:30am - 10:15am
  • Presented by Sanjib Das, PhD – Senior Scientist, Research

Poster #C0003: Fabrication of Shape and Size Specific Nanoparticles for Ocular Drug Delivery

  • Exhibit Hall 192414 3:45pm - 5:30pm
  • Presented by Stuart Williams, PhD – Director, Research

Thursday, May 7, 2015

Poster #C0136: Advancing ENV515 (travoprost) Intracameral Implant into Clinical Development: Nonclinical Evaluation of ENV515 in Support of First-Time-in-Human Phase 2a Clinical Study

  • Exhibit Hall 192358 8:30am - 10:15am
  • Presented by Tomas Navratil, PhD – Vice President, Development

Poster #A0068: Preclinical Evaluation of ENV905 (difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery

  • Exhibit Hall 193390 12:00pm - 1:45pm
  • Presented by Andres Garcia, MS – Senior Principal Scientist, Formulation Development

ABOUT ENVISIA THERAPEUTICS™

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. In January 2015, the company initiated a phase 2a clinical trial to investigate the safety and tolerability of ENV515 in patients with glaucoma. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.

Contacts

Media:
Envisia Therapeutics
Michael Parks, 484-356-7105
michael@pitch360inc.com

Contacts

Media:
Envisia Therapeutics
Michael Parks, 484-356-7105
michael@pitch360inc.com